XBH 25
Alternative Names: XBH-25Latest Information Update: 01 Jul 2022
At a glance
- Originator GV20 Oncotherapy
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immune checkpoint protein inhibitors; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Jul 2022 GV20 expects to file an IND application for XBH 25 in Solid tumours, in the second half of 2022
- 30 Jun 2022 GV20 plans clinical trials of XBH 25 in Solid tumours, in USA
- 18 Oct 2021 Preclinical trials in Solid tumours in China, USA (Parenteral) before October 2021 (GV20 Oncotherapy pipeline, October 2021)